Skip to main content
SpringerLink
Log in

A Randomized, Double-Blind, Multicenter Study Comparing a Starting Dose of 100 IU or 200 IU of Recombinant Follicle Stimulating Hormone (Puregon®) in Women Undergoing Controlled Ovarian Hyperstimulation for IVF Treatment

  • Assisted Reproduction
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose:: To compare the efficiency and efficacy of two starting doses of recombinant FSH (follitropin-β, Puregon) in women undergoing IVF treatment.

Methods: This prospective, randomized, double-blind, multicentric (N = 6) study included 192 women undergoing IVF using the long protocol of GnRH agonist who received either 100 IU or 200 IU of r-FSH per day. Gonadotropin dose adjustment was allowed after day 4 of stimulation.

Results: The average (SD) number of oocytes retrieved was 10.9 (5.4) and 12.2 (5.6) in the 100 IU and 200 IU group respectively (p = 0.067). The total doses of Puregon administered were 1887 IU and 2559 IU in the 100 IU and 200 IU group respectively. The number of transferable embryos, and the rates of pregnancies, cancelled cycles, miscarriages and adverse events including OHSS were comparable between the two groups.

Conclusions: Women undergoing IVF have similar outcomes whether recombinant FSH is commenced in a dose of 100 IU or 200 IU for the first 4 days of stimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Templeton A, Morris JK: Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 1998;339:573– 577

    Google Scholar 

  2. Tan SL, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, Brinsden P, Edwards RG, Jacobs HS: Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol 1994;171:513– 520

    Google Scholar 

  3. MacDougall MJ, Tan SL, Balen A, Jacobs HS: A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993;8:233– 237

    Google Scholar 

  4. Edwards RG, Lobo RA, Bouchard P: Why delay the obvious need for milder forms of ovarian stimulation? Hum Reprod 1997;12:399– 401

    Google Scholar 

  5. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z: Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;51:651– 654

    Google Scholar 

  6. Engmann L, Sladkevicius P, Agrawal R, Bekir J, Campbell S, Tan SL: The pattern of changes in ovarian stromal and uterine artery blood flow velocities during in vitro fertilization treatment and its relationship with outcome of the cycle. Ultrasound Obstet Gynecol 1999;13:26– 33

    Google Scholar 

  7. Zaidi J, Barber J, Kyei-Mensah A, Bekir J, Campbell S, Tan SL: Relationship of ovarian stromal blood flow at the baseline ultrasound scan to subsequent follicular response in an in vitro fertilization program. Obstet Gynecol 1996;88:779– 784

    Google Scholar 

  8. Schats R, Sutter PD, Bassil S, Kremer JA, Tournaye H, Donnez J: Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group. Hum Reprod 2000;15:1691– 1697

    Google Scholar 

  9. Frydman R, Howles CM, Truong F: A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists. Hum Reprod 2000;15:520– 525

    Google Scholar 

  10. Hoomans EH, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H: A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation. Hum Reprod 1999;14:2442– 2447

    Google Scholar 

  11. Brinsden P, Akagbosu F, Gibbons LM, Lancaster S, Gourdon D, Engrand P, Loumaye E: A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil Steril. 2000;73:114– 116

    Google Scholar 

  12. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco JA, Pellicer A: A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999;14:622– 627

    Google Scholar 

  13. Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B, Dirnfeld M: A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001;16:1104– 1109

    Google Scholar 

  14. Out HJ, Braat DD, Lintsen BM, Gurgan T, Bukulmez O, Gokmen O, Keles G, Caballero P, Gonzalez JM, Fabregues F, Balasch J, Roulier R: Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000;15:29– 35

    Google Scholar 

  15. van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA: Doubling the human menopausal gonadotrophin dose in the course of an in vitro fertilization treatment cycle in low responders: A randomized study. Hum Reprod 1993;8:369– 373

    Google Scholar 

  16. Harrison RF, Jacob S, Spillane H, Mallon E, Hennelly B. A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertil Steril 2001;75:23– 31

    Google Scholar 

  17. Jones HW Jr, Out HJ, Hoomans EH, Driessen SG, Coelingh Bennink HJ: Cryopreservation: The practicalities of evaluation. Hum Reprod 1997;12:1522– 1524

    Google Scholar 

  18. Sharif K, Elgendy M, Lashen H, Afnan M: Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome. Br J Obstet Gynaecol 1998;105:107– 112

    Google Scholar 

  19. Tinkanen H, Blauer M, Laippala P, Tuohimaa P, Kujansuu E: Prognostic factors in controlled ovarian hyperstimulation. Fertil Steril 1999;72:932– 936

    Article  Google Scholar 

  20. Lass A, Skull J, McVeigh E, Margara R, Winston RM: Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization can predict poor response. Hum Reprod 1997;12:294– 297

    Article  Google Scholar 

  21. Ng EH, Tang OS, Ho PC: The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme. Hum Reprod 2000;15:1937– 1942

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, McGill University, Royal Victoria Hospital, Montreal, Quebec, Canada

    Seang Lin Tan

  2. Oxford Fertility Unit, Women’s Centre, John Radcliffe Hospital, Oxford, United Kingdom

    Timothy J. Child

  3. UBC In Vitro fertilization Program, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada

    Anthony P. Cheung

  4. Department of Obstetrics and Gynecology, University of British Columbia, Grace Hospital, Vancouver, British Columbia, Canada

    Margo R. Fluker

  5. Genesis Fertility Centre, University of Western Ontario, Vancour, British Columbia, Canada

    Albert Yuzpe

  6. Division of Reproductive Sciences, Toronto General Hospital, Toronto, Ontario, Canada

    Robert Casper

  7. LIFE Program and IVF Canada, North York, Ontario, Canada

    Peter Leung

  8. S.T.A.R.T., Toronto, Ontario, Canada

    Kenneth Cadesky

  9. Department of Gynecology, Hospital For Sick Children, Toronto, Ontario, Canada

    Victoria J. Davis

Authors
  1. Seang Lin Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy J. Child
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony P. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margo R. Fluker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Albert Yuzpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenneth Cadesky
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Victoria J. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seang Lin Tan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, S.L., Child, T.J., Cheung, A.P. et al. A Randomized, Double-Blind, Multicenter Study Comparing a Starting Dose of 100 IU or 200 IU of Recombinant Follicle Stimulating Hormone (Puregon®) in Women Undergoing Controlled Ovarian Hyperstimulation for IVF Treatment. J Assist Reprod Genet 22, 81–88 (2005). https://doi.org/10.1007/s10815-005-1497-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-005-1497-1

Key words

Search

Navigation